Maravai LifeSciences (MRVI) Reports In-Line Q3 EPS
Tweet
Share
E-mail
Get Alerts MRVI Hot Sheet
Join SI Premium – FREE
Maravai LifeSciences (NASDAQ: MRVI) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $41.6 million versus the consensus estimate of $49.04 million.
For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
- Helius Medical Technologies (HSDT) Misses Q2 EPS by 31c
- OmniAb raises 2026 cash guidance on licensing activity
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
